Journal Article

Follow-up of children exposed antenatally to immunosuppressive drugs

M. Motta, A. Tincani, P. L. Meroni and R. Cimaz

in Rheumatology

Volume 47, issue suppl_3, pages iii32-iii34
Published in print June 2008 | ISSN: 1462-0324
Published online June 2008 | e-ISSN: 1462-0332 | DOI: http://dx.doi.org/10.1093/rheumatology/ken149
Follow-up of children exposed antenatally to immunosuppressive drugs

Show Summary Details

Preview

Antenatal exposure to immunosuppressive drugs given to mothers during pregnancy to treat autoimmune diseases raises some questions about the fetal development and the long-term outcome of children. Studies in humans showed that glucocorticoids (GCs), CsA and HCQ do not seem to increase the risk of congenital abnormalities; in contrast, cyclophosphamide, LEF and MTX are contraindicated during pregnancy. The risk of gestational complications, including pre-term delivery, intrauterine growth retardation (IUGR) and low birth weight (LBW), is higher in autoimmune diseases rather than in the general population and probably this finding is related to both maternal disorder and immunosuppressive therapy. Recently, results of our studies suggest that immunosuppressants given during pregnancy do not impair significantly the development of immunity in exposed children. Moreover, preliminary data on neurodevelopmental outcome seem to exclude a causative role of in utero exposure to immunosuppressive agents on the cognitive impairment observed in some of these children; however, our data need to be confirmed with further observations.

Keywords: Pregnancy; Autoimmune disease; Immunosuppressive drugs; Children

Journal Article.  2528 words. 

Subjects: Rheumatology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.